Interaction of innovative small molecule drugs used for cancer therapy with drug transporters
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 165, Issue 2, Pages 345-362
Publisher
Wiley
Online
2011-08-09
DOI
10.1111/j.1476-5381.2011.01618.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia
- (2011) Takeru Nambu et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib
- (2011) Yoshihiko Shibayama et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- [11C]Sorafenib: Radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice
- (2011) Chiharu Asakawa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics
- (2011) Atsushi Yonezawa et al. BRITISH JOURNAL OF PHARMACOLOGY
- Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2
- (2011) K Eechoute et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia
- (2011) Y Yamakawa et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Transporter-Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions
- (2011) O Zolk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
- (2011) Wei-Chien Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
- (2011) T. Minematsu et al. MOLECULAR CANCER THERAPEUTICS
- Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood−Brain Barrier
- (2011) Birk Poller et al. MOLECULAR PHARMACEUTICS
- Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
- (2011) Clara Lemos et al. PHARMACOGENOMICS
- Transporter-mediated drug–drug interactions
- (2011) Fabian Müller et al. PHARMACOGENOMICS
- Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
- (2011) M. Niemi et al. PHARMACOLOGICAL REVIEWS
- Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters
- (2011) Nicolas Picard et al. XENOBIOTICA
- Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
- (2010) Gabriele Buda et al. ANNALS OF HEMATOLOGY
- ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
- (2010) T. Mizuno et al. ANNALS OF ONCOLOGY
- Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines
- (2010) Maricla Galetti et al. BIOCHEMICAL PHARMACOLOGY
- Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene
- (2010) Haruka Kawahara et al. CANCER SCIENCE
- Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
- (2010) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation
- (2010) M. A. Elmeliegy et al. CLINICAL CANCER RESEARCH
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects
- (2010) Christina Fahrmayr et al. DRUG METABOLISM REVIEWS
- Drug transport by breast cancer resistance protein
- (2010) Maren Poguntke et al. Expert Opinion on Drug Metabolism & Toxicology
- Metabolism considerations for kinase inhibitors in cancer treatment
- (2010) Derek R Duckett et al. Expert Opinion on Drug Metabolism & Toxicology
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
- (2010) Naoto Takahashi et al. JOURNAL OF HUMAN GENETICS
- Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
- (2010) H. Kodaira et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain
- (2010) S. Agarwal et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1
- (2010) D L White et al. LEUKEMIA
- Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia
- (2010) Ling-Na Ni et al. MEDICAL ONCOLOGY
- A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP
- (2010) J. Perry et al. MOLECULAR CANCER THERAPEUTICS
- Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
- (2010) J. S. Lagas et al. MOLECULAR CANCER THERAPEUTICS
- Disposition of everolimus in mdr1a−/1b− mice and after a pre-treatment of lapatinib in Swiss mice
- (2009) C. Chu et al. BIOCHEMICAL PHARMACOLOGY
- Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
- (2009) Amit K. Tiwari et al. BIOCHEMICAL PHARMACOLOGY
- Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
- (2009) Ye-Hong Kuang et al. BIOCHEMICAL PHARMACOLOGY
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non–small-cell lung cancer
- (2009) Keiichi Akasaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
- (2009) Chun-ling Dai et al. CANCER LETTERS
- Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib
- (2009) Kohji Noguchi et al. CANCER SCIENCE
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
- (2009) S. Hu et al. CLINICAL CANCER RESEARCH
- Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
- (2009) D. H. Kim et al. CLINICAL CANCER RESEARCH
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
- (2009) L. Zhou et al. DRUG METABOLISM AND DISPOSITION
- Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
- (2009) Fabienne Thomas et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
- (2009) Nielka P. van Erp et al. JOURNAL OF CLINICAL ONCOLOGY
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
- (2009) D K Hiwase et al. LEUKEMIA
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C]gefitinib
- (2009) Kazunori Kawamura et al. NUCLEAR MEDICINE AND BIOLOGY
- Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
- (2009) Tong Shen et al. PLoS One
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
- (2008) S. Dulucq et al. BLOOD
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
- (2008) A. Giannoudis et al. BLOOD
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
- (2008) C.-l. Dai et al. CANCER RESEARCH
- Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
- (2008) J. R. Molina et al. CLINICAL CANCER RESEARCH
- Interaction of Imatinib with Human Organic Ion Carriers
- (2008) S. Hu et al. CLINICAL CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)
- (2008) J. W. Polli et al. DRUG METABOLISM AND DISPOSITION
- Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
- (2008) S. Shukla et al. DRUG METABOLISM AND DISPOSITION
- The role of hepatic transporters in drug elimination
- (2008) Christoph Funk Expert Opinion on Drug Metabolism & Toxicology
- Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation